Abstract: Nanomaterials of the JT phase of the titanium oxide TiO2-x, where 0?x?1 having as a building block a crystalline structure with an orthorhombic symmetry and described by at least one of the space groups 59 Pmmn, 63 Amma, 71 Immm or 63 Bmmb. These nanomaterials are in the form of nanofibers, nanowires, nanorods, nanoscrolls and/or nanotubes. The nanomaterials are obtained from a hydrogen titanate and/or a mixed sodium and hydrogen titanate precursor compound that is isostructural to the JT crystalline structure. The titanates are the hydrogenated, the protonated, the hydrated and/or the alkalinized phases of the JT crystalline phase that are obtained from titanium compounds such as titanium oxide with an anatase crystalline structure, amorphous titanium oxide, and titanium oxide with a rutile crystalline structure, and/or directly from the rutile mineral and/or from ilmenite.

Abstract: A catalyst that can be used for the production of hydrogen from hydrocarbon fuels in steam reforming processes contains an active metal of, e.g., at least one of Ir, Pt and Pd, on a catalyst support of, e.g., at least one of monoclinic zirconia and an alkaline-earth metal hexaaluminate. The catalyst exhibits improved activity, stability in both air and reducing atmospheres, and sulfur tolerance.

Abstract: The present invention relates to novel sequences for use in diagnosis and treatment of carcinomas, especially breast cancers. In addition, the present invention describes the use of novel compositions for use in screening methods. The invention provides compositions and methods associated with altered expression of PRLR in cancer.

Abstract: A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300° C., and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.

Abstract: One-part and two-part compositions curable by a metathesis reaction comprising a resin containing a polyether-based substrate with at least two cycloolefin groups per molecule curable by a metathesis reaction with a metathesis catalyst. These compositions may optionally contain a reaction control agent for slowing the progress of the metathesis reaction. The metathesis catalyst can be a ruthenium carbene complex catalyst. The substrate may be, for example, a difunctional urethane polyester or polyether carboxylate containing norbornenyl end groups.

Abstract: A nail polish composition comprises a cellulosic filmogenic polymer, a plasticizer and one or more solvents, and is characterized in that it includes 20 to 200% by weight, relative to the cellulosic polymer, of at least one second filmogenic polymer partially insoluble in the cellulosic polymer, giving rise to settling into at least two stable and separate liquid phases at rest. Preferably, the second filmogenic polymer is a vinyl resin, for example polyvinylbutyral. After agitation, this composition has a homogeneous appearance, and can be applied to the nails like a conventional polish.

Abstract: CTLA-8 related antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.

Abstract: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalamus.

Abstract: Methods of treating a retinal degenerative disorder.

Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.

Abstract: The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, the cells that can be treated with the cytokine antagonists are drug-resistant cancer cells which fail to undergo apoptosis.

Abstract: Humanized antibodies specifically binding to hTNF-? are prepared from a mouse monoclonal antibody by the CDR (complementarity determining region) grafting method, and they show an antigen binding affinity similar to the original mouse monoclonal antibody and significantly low immunogenicity. Therefore, the humanized antibodies can be effectively used for treating a hTNF-?-related disease such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis.

Abstract: Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and n which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response.

Abstract: This invention relates to a method of monitoring cancer development by determining the abundance of alpha-enolase protein wherein increased abundance is an indication of the severity of cancer. In another embodiment, the invention relates to a method of detecting cancer malignancy by determining the abundance of alpha-enolase antibodies in a sample wherein low levels of such antibodies indicates the malignancy of cancer. Also provided is a method of suppressing tumor growth by inducing the anti-ENO1 immune response.

Abstract: The present invention provides compounds having formula (I): wherein W1, W2, R1, R3, R4, R2A and R2B are as defined herein. In another aspect, the invention provides an antibody or antibody fragment which binds specifically to a normal or transformed PSA glycan or glycopeptide of the invention.

Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.

Abstract: The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.

Abstract: An emulsified cosmetic offering superior sensation of use and r stability comprises 0.1 to 25 wt % of aqueous moisturizing components, 2 to 80 wt % of oil solution components, and 0.1 to 30 wt % of spherical resin particles having hydrophilic groups on their surfaces and an average volume particle size of 2.0 ?m to 20.0 ?m. The spherical resin particles are made by applying alkali cleaning or acid cleaning to aggregation particles after resin polymerization, and the volume particle size distribution GSDv of the spherical resin particles is 1.3 or less, and the shape factor SF1 thereof is 100 to 140.

Abstract: A method is provided for sterilizing and/or deactivating adventitious agent(s) on and/or within a biological material which comprises packaging the biological material, altering the original atmosphere associated with the biological material in order to reduce the level of oxygen to which the biological material is exposed and subjecting the packaged biological material with its altered atmosphere to irradiation.

Abstract: Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies.

Abstract: Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies.

Abstract: The invention relates to the use of the hydrogenation products of frankincense (olibanum), its hydrogenated ingredients as well as physiologically acceptable salts and derivatives thereof and hydrogenated frankincense extracts for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease. The use of frankincense, frankincense extract, substances contained in frankincense, their physiologically acceptable salts, their derivatives and the physiological salts thereof, pure boswellic acids, tirucallic acids or other triterpenes, their physiologically acceptable salts, derivatives of the salts thereof for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia and/or cranial/brain trauma is also provided according to the invention.

Abstract: A method, apparatus and method of making acupoint patches is disclosed. The acupoint patch of the present invention uses natural herbs as raw materials. It is made by combining traditional Chinese acupuncture therapy and contemporary transdermal controlled release technologies. The acupoint patch of the present invention is made with natural herb extracts using contemporary transdermal absorption technologies based on the characteristics of different acupoints. They can stay on the skin for 6-8 hours, during which period natural herb essence enters blood circulation and performs a sustainable regulating function. This is a feature unrivaled by traditional acupuncture.

Abstract: The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species with an alcohol-based solvent in the presence of an acetic acid solution to form an extract composition, (b) subjecting a resultant product obtained in step (a) to obtain a soluble fraction, and (c) removing solvent from the soluble fraction obtained in step (b) to obtain the extract product.

Abstract: The present invention relates to extracts containing beneficial plant secondary metabolites. In particular the present invention relates to plant extracts from butter trees and methods of producing such extracts. Applications of these extracts are furthermore disclosed herein.

Abstract: A process for preparing a processed ginseng extract with enhanced pharmacological effects due to subsequent treatment is disclosed. The subsequent treatment includes an acid-treatment of ginseng and a bio-converting treatment, such as a lactic acid bacterial fermenting and an intestinal bacterial fermenting process.

Abstract: The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, omithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids.

Abstract: The present invention provides a method for the preparation of a plant jelly in the form of a jelly-like product wherein selected phospholipids (for example, PC, PE and lyso-PC/PE) play an important role in jellifying the mixture. The plant jelly has a plant hard fat blend and an oil blend in which the plant hard fat blend is made up of about 10-20% of a fat with a melting point of 30-40° C. and about 4-10% of a vegetable fat, and in which the oil blend is made up of about 1-3.5% phospholipids and about 70-80% liquid oil.

Abstract: Canola oil seeds are treated for the production of a canola oil seed meal for recovery of canola protein isolates therefrom. The canola oil seeds are heat-treated to inactivate myrosinases and other enzymes and dehulled prior to crushing dehulled canola oil seeds and removing oil therefrom and to provide the canola oil seed meal.

Abstract: Methods of using pomegranate extracts of the present invention for treating patients with atherosclerosis, or increased intima-media thickness of an artery, are provided. The methods comprise the step of administering to the patient a composition comprising a therapeutically effective amount of an extract from pomegranate. The methods of the present invention may also be used to decrease the incidence of stroke or heart attack in a patient.

Abstract: Disclosed are flavored nutritional beverages comprising (A) fat; (B) milk protein representing from about 10% to 100% by weight of total protein; (C) carbohydrate comprising from about 75% to 100% by weight of at least one of (i) from about 0.1% to about 10% sucrose, trehalose, or combination thereof, by weight of the beverage, and (iii) from about 0.1% to about 20% maltodextrin by weight of the nutritional liquid, the maltodextrin having a DE value of from about 1 to about 10, and (iii) combinations of (i) and (ii); (D) an iron-containing material, and (E) a flavorant. The flavored nutritional beverages, unlike many iron-fortified milk-based beverages available today, do not readily develop beige or gray hues during formulation, processing and storage, and are thus more easily formulated with little or no color distortion and with improved or more accurately matched flavor-color combinations.

Abstract: A process of coating an animal feed to obtain a coated animal feed product is provided. The process includes the step of applying a first coating to the animal feed, wherein the first coating comprises at least 20% by weight of sugar selected from the group consisting of monosaccharide, disaccharide, and any combination thereof in any proportion. The process also includes the step of applying a second coating to the animal feed, wherein the second coating comprises at least 20% by weight of phospholipid.

Abstract: A return liquid containing particles resulting from treating food is treated to reduce the size of the particles and recycled for further food treatment. Embodiments include injecting a solution into a body of meat, recovering a return solution containing particulate material resulting from injecting the body of meat, optionally reducing the temperature of the return solution, mechanically reducing the particle size of the particulate material in the return solution to form a reduced return solution, conveying the reduced return solution to a holding tank and recycling the reduced return solution for injection into a body of meat. Embodiments also include a system for recycling a food treating liquid including a mechanical milling device, an optional chilling device, and a holding tank including first, second and third sections, a first weir separating the first and second sections, and a second weir separating the second and third sections, wherein the second weir extends higher than the first weir.

Abstract: A vegetable fat composition comprises glycerides, wherein the triglyceride content of the composition is: 6 to 20% SSS, 5 to less than 20% SUS 5 to less than 25% SSU 10 to 39% SU2 and at least 20% U3, wherein S is a saturated fatty acid residue having 16 to 24 carbon atoms and U is an unsaturated fatty acid residue having at least 18 carbon atoms and all percentages are by weight based on the total triglycerides present in the composition, the weight ratio SUS/SSU is between 0.5 and 2.0, the weight ratio of (saturated fatty acid residues having 18 to 24 carbon atoms)/(saturated fatty acid residues having 16 carbon atoms) in the total S content of the triglycerides is less than 0.2, and the triglycerides contain less than 3% of arachidic and behenic acid residues based on the total fatty acid residue content of the triglycerides, and wherein the saturated fatty acid residue content of the triglycerides is less than 45% by weight of the total fatty acid residues in the triglycerides.

Abstract: A method and system for purifying polymers to use with medical devices, particularly for a drug eluting stent, is described.

Abstract: A method for forming a randomly textured surface on an implantable device such as soft tissue prosthesis. The textured surface has numerous cavities, interstices and passageways or tunnels and is thus referred to as a microporous surface texture. The surface is formed by two or more applications of polymeric particles and a polymeric dispersion.

Abstract: An interventional device for delivery of beneficial agent to a lumen and methods of loading and manufacture of the same, which include a prosthesis loaded with beneficial agent to provide a controlled dosage concentration of beneficial agent to the lumen. The beneficial agent is loaded onto the prosthesis by a fluid-dispenser having a dispensing element capable of dispensing the beneficial agent in discrete droplets, each droplet having a controlled trajectory. The method of loading beneficial agent includes dispensing beneficial agent in a raster format and/or an off-axis format along a dispensing path.

Abstract: An apparatus and method for simultaneously coating and measuring a part including a part support, a sprayer, a part measurer including a digital camera and a display device, all of which are positioned adjacent to the part support. The sprayer applies a coating to a section of the part while the part measurer continuously measures at least two dimensions of the section. The digital camera takes at least one picture of the entire section of the part while the part is being coated and enables a user to accurately determine the cross section of the part to the optimum finished part configuration and size and also detect defects, blemishes or coating irregularities formed on the section. The apparatus and method of the present invention significantly reduces the margin of error related to the application of coatings to parts, the number of defective parts and increases the overall efficiency.

Abstract: Methods of forming displays are described. The displays have zinc oxide row and column drivers integrated onto the same display substrate as zinc oxide pixel transistors and organic light emitting diodes. The organic light emitting diodes are prepared, at least in part, using a thermal transfer process from a donor sheet.

Abstract: A thermal management process for enabling the restoration of a surface of a metallic detail in the presence of at least one bonding material, comprising preparing at least one damaged area on a metallic detail; disposing at least one thermal management component upon a bonding material or a surface area proximate to the bonding material to which the metallic detail is joined; masking at least the surface area and the bonding material with a masking agent; and dimensionally restoring a surface of the metallic detail disposed on the article at a processing temperature lower than a temperature which would degrade the bonding material, the substrate, or the bondment interface therebetween.

Abstract: The invention relates to a procedure for applying pictures, preferably color pictures, in the surface of a glass article. The pictures are separated by color to make different templates for different colors, e.g. for silk screen printing, or for another method to apply the color on the glass. The colors are then fired according to a schedule of temperature sequences, to get the colors melt into the surface of the glass article to solidity on level with that surface.

Abstract: The present invention relates to a method of lowering dielectric constant of an insulating film including Si, O and CH formed by a chemical vapor deposition process. A process gas containing hydrogen atoms is supplied into a reaction vessel. A microwave is introduced into the reaction vessel to supply a uniform electromagnetic wave, thereby a plasma containing a hydrogen radical is generated in the reaction vessel. The structure of the insulating film is modified by the hydrogen radical contained in the plasma irradiated to the insulating film, lowering the dielectric constant of the film. The microwave is supplied into the reaction vessel through a radial-slot antenna.

Abstract: Systems and methods for synthesizing long carbon nanotubes and using the nanotube as an electrical conductor. A substrate is provided with one or more metal underlayer platforms that allow the nanotube to grow freely suspended from the substrate. A modified gas-flow injector is used to reduce the gas flow turbulence during nanotube growth. Nanotube electrodes are formed by growing arrays of aligned nanotubes between two metal underlayer platforms.

Abstract: A method for forming a layer on a surface in making a device, including providing a distribution member for receiving vaporized material, the distribution member having one or more walls defining a polygonal two-dimensional pattern of apertures is formed in a wall, which deliver vaporized material in a molecular flow onto the surface; providing the polygonal two-dimensional pattern of apertures to have at least four vertices, with a first set of apertures disposed at the vertices, a second set of edge apertures disposed between the apertures of the first set and defining the edges of the polygonal two-dimensional pattern, and a third set of interior apertures disposed within the periphery of the polygonal two-dimensional pattern defined by the first and second sets of apertures; and dimensioning the apertures to obtain a desired flow rate.

Abstract: A method for forming a metal carbide or metal carbonitride film on a substrate using a vapor deposition process. The method includes comprises introducing a first process material, such as a film precursor, to the substrate followed by introducing a second process material, such as a film reducing agent, to the substrate, whereby plasma can be formed during the introduction of the second process material in order to assist reduction of the first process material on the substrate. Additionally, the temperature of the substrate is elevated to a value approximately equal to or greater than the decomposition temperature of the first process material in order to improve adhesion properties for the metal carbide or metal carbonitride film.

Abstract: There is provided a method for applying an improved chromium diffusion coating on an industrial item such as a turbine blade of a gas turbine engine. Chromium and other active metals are combined to form an alloy coating. Active elements include silicon, hafnium, zirconium, yttrium, tantalum, and rhenium. For producing the modified coatings through pack cementation chromium and a master alloy are mixed into a packing along with inert material and a halide activator. The packing surrounds a target in a diffusion box. The metals are then deposited by diffusion onto a target surface by pack cementation methods. The diffusion of the desired metals takes place during a coating thermal cycle. Alternatively, the diffusion can take place using an out-of-pack arrangement. Such modified coatings are utilized as improved performance coatings for environmental resistance applications over the current chromium diffusion coatings.

Abstract: The invention relates to a of manufacturing a silicon dioxide layer of low roughness, that includes depositing a layer of silicon dioxide over a substrate by a low pressure chemical vapor deposition (LPCVD) process, the deposition process employing simultaneously a flow of tetraethylorthosilicate (TEOS) as the source material for the film deposition and a flow of a diluant gas that it not reactive with TEOS, so that the diluant gas/TEOS flow ratio is between 0.5 and 100; and annealing the silicon dioxide layer at a temperature between 600° C. and 1200° C., for a duration between 10 minutes and 6 hours.

Abstract: In certain example embodiments, a coated article includes a Zn-doped zirconium based layer before heat treatment (HT). The coated article is heat treated sufficiently to cause the Zn-doped zirconium based layer to transform into a Zn-doped zirconium oxide based layer that is scratch resistant and/or chemically durable. The doping of the layer with Zn has been found to improve scratch resistance and/or corrosion resistance.

Abstract: A method for producing weather- and corrosion-resistant shaped sheets consisting of aluminum or an aluminum alloy with a decorative finish in a coil coating process that comprises the following sequential steps: an aluminum strip or aluminum alloy strip is provided; optional continuous degreasing of the strip; optional electrochemical, chemical or mechanical burnishing of the optionally degreased strip; the optionally degreased and/or burnished strip is continuously pre-treated to create a pre-treated layer that is suitable for use as an adhesive base for a paint layer; the optionally degreased strip is continuously pre-treated to create a strip surface that is suitable for use as an adhesive base for a paint layer; the pre-treated strip is continuously painted with a sol-gel paint consisting of a polysiloxane to create a first protect protective layer; the first protective layer is continuously dried and cured in a continuous furnace; the sheets are produced by shaping the strip that comprises the first prot